JP2023524039A - Ｔ型カルシウムチャネルモジュレーターを使用する方法 - Google Patents

Ｔ型カルシウムチャネルモジュレーターを使用する方法 Download PDF

Info

Publication number
JP2023524039A
JP2023524039A JP2022566066A JP2022566066A JP2023524039A JP 2023524039 A JP2023524039 A JP 2023524039A JP 2022566066 A JP2022566066 A JP 2022566066A JP 2022566066 A JP2022566066 A JP 2022566066A JP 2023524039 A JP2023524039 A JP 2023524039A
Authority
JP
Japan
Prior art keywords
dose
compound
subject
period
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524039A5 (https=
Inventor
キラン レディ，
ガブリエル ベルフォート，
バーナード ラヴィーナ，
マリオン ウィットマン，
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2023524039A publication Critical patent/JP2023524039A/ja
Publication of JP2023524039A5 publication Critical patent/JP2023524039A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transmitters (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022566066A 2020-04-29 2021-04-28 Ｔ型カルシウムチャネルモジュレーターを使用する方法 Pending JP2023524039A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063017140P 2020-04-29 2020-04-29
US63/017,140 2020-04-29
US202063050410P 2020-07-10 2020-07-10
US63/050,410 2020-07-10
US202063082946P 2020-09-24 2020-09-24
US63/082,946 2020-09-24
PCT/US2021/029539 WO2021222342A1 (en) 2020-04-29 2021-04-28 Methods of use of t-type calcium channel modulators

Publications (2)

Publication Number Publication Date
JP2023524039A true JP2023524039A (ja) 2023-06-08
JP2023524039A5 JP2023524039A5 (https=) 2024-05-09

Family

ID=78373913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566066A Pending JP2023524039A (ja) 2020-04-29 2021-04-28 Ｔ型カルシウムチャネルモジュレーターを使用する方法

Country Status (11)

Country Link
US (1) US20230165847A1 (https=)
EP (1) EP4142764A4 (https=)
JP (1) JP2023524039A (https=)
KR (1) KR20230018384A (https=)
CN (1) CN115776894A (https=)
AU (1) AU2021263804A1 (https=)
BR (1) BR112022021946A2 (https=)
CA (1) CA3177277A1 (https=)
IL (1) IL297642A (https=)
MX (1) MX2022013595A (https=)
WO (1) WO2021222342A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996746A4 (en) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
US20250170114A1 (en) * 2022-02-03 2025-05-29 Praxis Precision Medicines, Inc. Methods of treatment using t-type calcium channel modulators
WO2023192885A2 (en) * 2022-03-28 2023-10-05 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators
AU2024229946A1 (en) * 2023-03-02 2025-09-11 Praxis Precision Medicines, Inc. Crystalline salts of a t-type calcium channel modulator and methods of use thereof
CN121127456A (zh) * 2023-03-02 2025-12-12 普拉西斯精密医药公司 N-((1-(2-(叔丁基氨基)-2-氧代乙基)哌啶-4-基)甲基)-3-氯-5-氟苯甲酰胺的结晶盐形式和其使用方法
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
DK3364993T3 (da) * 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
EP3340988B1 (en) * 2015-11-12 2025-04-09 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
MX388586B (es) * 2016-12-16 2025-03-20 Idorsia Pharmaceuticals Ltd Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t.
MY204493A (en) * 2017-11-10 2024-08-30 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disorders
TWI879741B (zh) * 2018-10-03 2025-04-11 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J MANAG CARE SPEC PHARM, vol. 24, no. 9, JPN6025018218, 2018, pages 929 - 938, ISSN: 0005779378 *

Also Published As

Publication number Publication date
KR20230018384A (ko) 2023-02-07
EP4142764A4 (en) 2024-05-29
MX2022013595A (es) 2023-01-24
AU2021263804A1 (en) 2023-01-19
BR112022021946A2 (pt) 2023-01-17
CA3177277A1 (en) 2021-11-04
EP4142764A1 (en) 2023-03-08
IL297642A (en) 2022-12-01
WO2021222342A1 (en) 2021-11-04
US20230165847A1 (en) 2023-06-01
CN115776894A (zh) 2023-03-10

Similar Documents

Publication Publication Date Title
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
JP2023524039A (ja) Ｔ型カルシウムチャネルモジュレーターを使用する方法
KR20180031721A (ko) 가복사돌로 발달장애들을 치료하는 방법들
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
EP4472633A2 (en) Methods of treatment using t-type calcium channel modulators
JP2026507195A (ja) 高用量単回投与製剤及びその使用の方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260126